Vident Advisory, LLC Recursion Pharmaceuticals, Inc. Transaction History
Vident Advisory, LLC
- $3.62 Trillion
- Q2 2024
A detailed history of Vident Advisory, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 18,363 shares of RXRX stock, worth $127,990. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,363
Previous 18,761
2.12%
Holding current value
$127,990
Previous $187 Million
26.37%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RXRX
# of Institutions
291Shares Held
239MCall Options Held
984KPut Options Held
2.4M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$228 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$176 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$150 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$121 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$107 Million1.74% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.26B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...